Accéder au contenu
Merck
  • Peripheral Intravenous Volume Analysis (PIVA) for Quantitating Volume Overload in Patients Hospitalized With Acute Decompensated Heart Failure-A Pilot Study.

Peripheral Intravenous Volume Analysis (PIVA) for Quantitating Volume Overload in Patients Hospitalized With Acute Decompensated Heart Failure-A Pilot Study.

Journal of cardiac failure (2018-05-20)
Merrick Miles, Bret D Alvis, Kyle Hocking, Franz Baudenbacher, Christy Guth, Joann Lindenfeld, Colleen Brophy, Susan Eagle
RÉSUMÉ

To determine the feasibility of peripheral intravenous volume analysis (PIVA) of venous waveforms for assessing volume overload in patients admitted to the hospital with acute decompensated heart failure (ADHF). Venous waveforms were captured from a peripheral intravenous catheter in subjects admitted for ADHF and healthy age-matched controls. Admission PIVA signal, brain natriuretic peptide, and chest radiographic measurements were related to the net volume removed during diuresis. ADHF patients had a significantly greater PIVA signal on admission compared with the control group (P = .0013, n = 18). At discharge, ADHF patients had a PIVA signal similar to the control group. PIVA signal, not brain natriuretic peptide or chest radiographic measures, accurately predicted the amount of volume removed during diuresis (R2 = 0.781, n = 14). PIVA signal at time of discharge greater than 0.20, demonstrated 83.3% 120-day readmission rate. This study demonstrates the feasibility of PIVA for assessment of volume overload in patients admitted to the hospital with ADHF.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
(+)-Biotin 4-nitrophenyl ester, 98%